Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

A series of new revelations has come to light about the FDA's delay in granting full approval to Novavax's COVID-19 shot, thanks to recent reporting from the Wall Street Journal and STAT News.

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

According to an internal email, the agency may be in for more consolidation in areas including human resources, ...

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

Although vaccines may have a tougher time winning the endorsement of the CDC's Advisory Committee on Immunization Practices ...

The variant - NB.1.8.1 is nicknamed Nimbus aka 'razor blade throat' Covid as it may cause painful sore throats and doctors in ...